References Ewy
1. Compston, A. Coles, A. Lancet 2002, 359, 1221-1231. 2. Goodin, D. S. Frohman, E. M. Garmany, G. P, Jr. Halper, J. Likosky, W H. Lublin, F D. Silberberg, D. H. Stuart, W H. van der Noort, S. Neurology 2002, 58, 169-178. 3. Kreitman, R. R. Blanchette, F Mult. Scler. 2004, 10, 581-589. 4. Teitelbaum, D. Meshorer, A. Hirshfeld, T. Sela, M. Arnon, R. Eur. J. Immunol. 1971, 1, 242-248. 5. Teitelbaum, D. Aharoni, R. Fridkis-Hareli, M. Arnon, R. Sela, M. Development of Copolymer 1 Copaxone as a...
Raloxifene
J Lewis-Wambi and V C Jordan, Fox Chase Cancer Center, Philadelphia, PA, USA 2007 Elsevier Ltd. All Rights Reserved. 8.09.1 Background and Introduction 103 8.09.2 Evolution of Antiestrogens to Raloxifene 106 8.09.3 Complex Patenting 107 8.09.4 Raloxifene Structural Characteristics 108 8.09.5 Raloxifene and Bone 109 8.09.6 Raloxifene and Breast Cancer Prevention 111 8.09.7 Raloxifene and Lipids 113 8.09.8 Other Selective Estrogen Receptor Modulators 115 8.09.13 Conclusion 116 References 117
The Discovery of Lopinavir and the Development of Kaletra LopinavirRitonavir
As mentioned previously, the evaluation of the antiviral potency of new protease inhibitors in the discovery program was expanded to include assays in the presence of 50 human serum, to best estimate 'in vivo potency.' Following the observation of substantial boosting by ritonavir, the preclinical pharmacokinetic screening protocol was also modified to include evaluation in rats and dogs, both alone and following codosing with ritonavir. The goal for an advanced generation protease inhibitor...
Lasofoxifene
Lasofoxifene Figure 10 is a novel nonsteroidal SERM that is in clinical trials for the prevention and treatment of osteoporosis in postmenopausal women.195 It is a diaryltetrahydronaphthalene derivative referred to as CP336156. The structure of CP336156 is reminiscent of nafoxidine Figure 3 if it were to be demethylated in vivo. There are two diastereometric salts. CP336156 is the L enantiomer that has 20 times the binding affinity of the D enantiomer. Studies Figure 10 Bazedoxifene,...
The Chemistry of Copaxone
Copaxone Copolymer 1 is a synthetic amino acid copolymer which is prepared by polymerization of the monomers, N-carboxy a-amino acid anhydrides. These anhydrides are obtained by reacting the respective amino acids with phosgene in dioxane. The anhydrides may be readily polymerized to form amino acid polymers.9 The polymerization is usually carried out in inert solvent such as dioxane, in the presence of suitable initiator amines or strong bases. In this type of polymerization a growing chain...
Comprehensive Medicinal Chemistry II Volume 8 Case Histories
Editors-in-Chief John B. Taylor and David J. Triggle ISBN 0-08-044513-6 set 8.01 Introduction, Pages 1-5, W.T. Comer 8.02 Reflections on Medicinal Chemistry Since the 1950s, Pages 7-15, H. Timmerman 8.03 Medicinal Chemistry as a Scientific Discipline in Industry and Academia Personal Reflections, Pages 17-27, C.R. Ganellin 8.04 Some Aspects of Medicinal Chemistry at the Schering-Plough Research Institute, Pages 29-51, A.K. Ganguly 8.05 Viread, Pages 53-58, R. Oliyai and M. Fardis 8.06 Hepsera,...
Urge Urinary Incontinence and Overactive Bladder
Interestingly, the impetus for studying duloxetine was for discovering a treatment of urinary urge incontinence and overactive bladder. Insertion of EMG electrodes into the rhabdosphincter was a compulsion instilled in me during my dissertation studies to obtain as much data as practical from every experiment conducted. Even after seeing pronounced effects on the rhabdosphincter, I was still more impressed with the effects on the bladder and anticipated clinical benefits for urge incontinence...
Carbazol antioxidant
Over the next decade, compelling data were generated in a variety of in vitro and in vivo experimental systems that highlighted novel and unusually effective cardioprotective properties of the drug that resulted in part from the beneficial hemodynamic effects emanating from beta blockade and alpha blockade, and in part from the unique antioxidant, antiapoptotic, and antiproliferative properties of the molecule. Based on these extensive studies, the highest levels of corporate and R amp D...
Design of SymmetryBased Human Immunodeficiency Virus Protease Inhibitors
The discovery of HIV protease inhibitors began with one of the first applications of modern genomics in medicine. Shortly after the isolation and identification of HIV as the causative agent for AIDS, its entire retroviral genome was sequenced and homology modeling2 revealed a genetic motif Asp-Thr-Gly suggestive of an aspartic proteinase HIV protease . HIV encodes its structural and enzymatic proteins in the gag and pol genes, respectively, and translation provides large gag and gag-pol...
Introduction Pug
Multiple sclerosis MS is an inflammatory disease of the central nervous system CNS that leads to myelin destruction and axonal loss. It is the most common, nontraumatic, disabling neurological disorder in young adults. While the etiology of MS remains unknown, its pathogenesis involves autoimmune reactivity to various myelin antigens such as myelin basic protein MBP , proteolipid protein PLP , myelin oligodendrocyte glycoprotein MOG , and other myelin minor components. MS is often characterized...
The Discovery of Ritonavir Norvir
A significant improvement on the rapid clearance of A-80987 was achieved in subsequent SAR studies. In vitro metabolism studies in human liver microsomes indicated that N-oxidation of the pyridyl groups of both A-77003 and A-80987 occurred rapidly to produce the major metabolites. Systematic studies in which each of the two pyridyl groups were independently replaced with thiazolyl groups, which were more stable to oxidation, suggested that further improvements in the pharmacokinetics of A-80987...
Figure 5 ac PKPD model for resistance development for HIV protease inhibitors d
sufficient resistance to overcome all drug concentrations encountered in a dosing cycle are produced, the drug loses its antiviral effect, and viral load rebounds to pretherapy levels Figure 5a-c . This PK PD resistance model suggested that resistance could be delayed or prevented if a the drug was substantially more potent i.e., much lower EC50 , and or b the drug maintained higher plasma concentrations particularly trough concentrations Figure 5d . Both of these goals were realized with the...
The First Step The Discovery of Adrafinil
In the early 1970s, the Research Department of Laboratoire Louis Lafon, a small family-owned pharmaceutical company located in Maisons-Alfort, a suburb of Paris, had focused its research activities in three areas 1 cardiovascular 2 antispasmodics and 3 nonsteroidal anti-inflammatory drugs NSAIDs analgesics. In this last field, an empirical test battery was implemented, using the best-characterized in vivo pharmacological methods generally in use at that time some of which are still used . These...
Figure 5 Responder analysis of 20 mg qd duloxetine DUL versus placebo PL as
Figure 6 Effects of placebo P and duloxetine D at 20, 30, 40 mg q.d. on stress-pad test SPT , incontinence episode frequency IEF , 24-h pad weight 24PT , and incontinence quality of life IQOL in SUI patients. Adapted from Zinner, N. Sarshik, S. Yalcin, I. Faries, D. DeBrota, D. Riedl, P. Thor, K.B. Efficacy and Safety of Duloxetine in Stress Urinary Incontinent Patients Double-Blind, Placebo-Controlled Multiple Dose Study. International Continence Society, 28th Annual Meeting, Jerusalem,...
P 005 P 001
Figure 8 Responder analysis of 20, 30, and 40 mg q.d. duloxetine D versus placebo Pla as defined by a 70 improvement from baseline in SUI patients. Adapted from Zinner, N. Sarshik, S. Yalcin, I. Faries, D. DeBrota, D. Riedl, P. Thor, K.B. Efficacy and Safety of Duloxetine in Stress Urinary Incontinent Patients Double-Blind, Placebo-Controlled Multiple Dose Study. International Continence Society, 28th Annual Meeting, Jerusalem, Israel, Sept. 199S. Figure 8 Responder analysis of 20, 30, and 40...
Synthesis
A number of syntheses of ezetimibe and related compounds have been reported, several of which were utilized in the course of these investigations.31-38 Many of these are based on an Evans-type oxazolidinone condensation to establish the correct stereochemistry on the azetidinone ring. Figure 22 shows a representative synthesis of ezetimibe. In addition to the use of the oxazolidinone, this synthesis also features a Corey oxazaborolidine reduction to set the S stereochemistry of the side chain...
The Multiple Actions of Carvedilol Antioxidant Properties
However, following detailed medical and commercial analyses, the company decided not to aggressively pursue the indications of angina and hypertension for a number of reasons 1 there was little medical need for another drug to treat these disorders, 2 there were, at the time, no known properties of carvedilol to differentiate the drug from others in the class, 3 generic beta blockers were already available and in wide use, and 4 due to the high promotional expenditure that would be required to...
Some Aspects of Medicinal Chemistry at the ScheringPlough Research Institute
A K Ganguly, Stevens Institute of Technology, Hoboken, NJ, USA 2007 Elsevier Ltd. All Rights Reserved. 8.04.2 The Discovery of Ezetimibe 30 8.04.2.1 The Synthesis and Biological Activities of Initial Leads 31 8.04.2.2 The Discovery of SCH 48461 31 8.04.2.3 The In Vivo Activity of SCH 48461 32 8.04.2.4 The Design of Ezetimibe 33 8.04.2.5 The Synthesis of Ezetimibe 34 8.04.2.6 The Biological Activity of Ezetimibe 34 8.04.2.7 The Results of Clinical Trials of Ezetimibe 35 8.04.2.7.1 The mechanism...
Beta Blockers in Heart Failure Perspectives
The decision not to develop carvedilol for cardioprotection caused us to rethink what we could do with this very novel drug a drug unlike any other we had ever studied. We discussed the absurd possibility of studying carvedilol, a beta blocker, in congestive heart failure with a number of prominent cardiologists, and most were not interested in this prospect, and some were, quite frankly, astonished by such a radical proposal to use a contraindicated drug in such seriously ill patients. But we...
The Development of a Viable Synthesis of Oxazolidinones with High Enantiomeric
At the beginning of our oxazolidinone exploratory project, we had elected to work with racemic compounds as a means of enabling the rapid SAR exploration and discovery of proprietary oxazolidinone series. The route we chose to the racemic oxazolidinones exploited an iodocyclocarbamation reaction, first developed by Fraser-Reid,37 and subsequently employed by others38'39 in a more closely related sense to our work. Our use of this iodine-mediated cyclization of N-allyl carbamates was the first...
Immunological Properties of Glatiramer Acetate
Several immunological properties of GA are thought to contribute to the effects of GA. 8.14.4.1.1 Binding to major histocompatibility complex molecules GA exhibits a very rapid, high, and efficient binding to many different MHC class II haplotypes on living murine and human antigen-presenting cells APCs . GA was also shown to interact with purified human leukocyte antigen HLA -DR molecules - DR1, DR2, and DR4 - with high affinity.45 As a result of its high and efficient binding to MHC class II...
References Ygu
1. De Lecea, L. Kilduff, T S . Peyron, C . Gao, X. Foye, P E . Danielson, P E . Fukuhara, C . Battenberg, E . L. Gautvik, V T Bartlett, F S . , II et al. Proc. Natl. Acad. Sci. USA 1998, 95, 322-327. 2. Chemelli, R. M. Willie, J. T. Sinton, C. M. Elmquist, J. K. Scammell, T Lee, C. Richardson, J. A. Williams, S. C. Xiong, Y Kisanuki, Y et al. Cell 1999, 98, 437-451. 3. Mignot, E. Taheri, S. Nishino, S. Nat. Neurosci. 2002, 1071-1075. 4. Jones, B. E. Front. Biosci. 2003, 8, s438-s451. 5....
Concerns about Tamoxifen
During the 1990s several important aspects of the pharmacology of tamoxifen emerged that had an impact on the clinical use of the drug. Each aspect was to create severe problems for developing the medicine from a treatment to a chemopreventive. Nevertheless, the rigorous evaluation of tamoxifen proved to be invaluable to understand the actions of the drug fully so that a solid clinical data base could be used to introduce improved medicines. There were three principal areas of concern. First,...
Tamoxifen
V C Jordan, Fox Chase Cancer Center, Philadelphia, PA, USA 2007 Elsevier Ltd. All Rights Reserved. 8.08.1 Background and Introduction 83 8.08.2 Nonsteroidal Antiestrogens 83 8.08.3 The Discovery of ICI46,474 86 8.08.4 Studies Published by Scientists at ICI Pharmaceuticals Division 86 8.08.5 Patenting Problems 88 8.08.6 A Conversation between the Laboratory and the Clinic 89 8.08.7 Twenty-First Century View of Tamoxifen as a Treatment for Breast Cancer 91 8.08.8 Concerns about Tamoxifen 91...
Lower Urinary Tract Function and Dysfunction
The function of the lower urinary tract is to store and periodically release urine.1 The lower urinary tract is composed primarily of smooth muscle that forms a reservoir the urinary bladder and an outlet the urethra , which has a 'valve' -the urethral rhabdosphincter - that is composed of striated muscle. Regulation and coordination of urine storage and release i.e., micturition is accomplished by a series of spinal and spinobulbospinal reflexes, respectively Figure 1 . These reflexes can be...
GP GH Lopinavir ABT378
Figure 2 Structures of symmetry-based HIV protease inhibitors A-74704, A-77003, A-80987, ritonavir ABT-538 , and lopinavir ABT-378 . Figure 3 Binding of diastereomeric diols in the HIV protease active site. a Overlap of the central portions of S,S-diol A-76928, green and R,R-diol A-76889, magenta . Hydroxyl groups red are projected down toward the catalytic aspartates. b Overlap of the above inhibitors with the R,S-diol A-77003, blue , showing the shift from symmetry to allow the R-hydroxyl...
Conclusion 1
Adefovir dipivoxil Hepsera is an excellent example of a prodrug that can overcome the oral delivery problem associated with poor permeation across the intestinal mucosa. Since its launch in 2002, Hepsera has become an important agent for the treatment of hepatitis B patients with evidence of active viral replication. A safety profile similar to placebo has been observed for Hepsera, which allows it to be prescribed as an effective drug for chronic treatment of hepatitis B. 1. World Health...
Demonstration of a StructureToxicity Relationship A Strategy for Lead
Fairly early on in our exploratory project we had identified one particularly interesting compound that demonstrated very good in vitro potency and oral in vivo efficacy comparable to DuP-721, and was found to have similar PK properties in the rat. This was the indanone oxazolidinone -U-82965 5, PNU-82965 ,24,25 one of two cyclic ketones we had targeted in order to explore the consequence of restricting the rotational conformers of the DuP-721 methyl ketone, via constraint in a five- or...
From Adrafinil to Modafinil
In considering adrafinil as a lead compound in search of therapeutic utility, the Chemistry Department in Laboratoire L. Lafon began to synthesize compounds chemically related to adrafinil. More than 100 compounds were then characterized using the primary behavioral screening used to determine the effects of adrafinil. In April 1976, 2 years after the first assays with adrafinil, CRL40476 was identified. This compound displayed the same pharmacological profile as adrafinil, but was more potent...
References Jjz
1. Culbertson, J. Cowan, M. C. Living Agents of Disease GP Putnam's Sons New York, 1952. 2. Barber, M. Garrod, L. P Antibiotic and Chemotherapy Williams and Wilkins Baltimore, MD, 1963. 3. Franklin, T J. Snow, G. A. Biochemistry of Antimicrobial Action Academic Press New York, 1971. 4. Lesher, G. Y Froelich, E. J. Gruett, M. D. Bailey, J. H. Brundage, R. P J. Med. Pharm. Chem. 1962, 5, 1063-1068. 5. Walsh, C. Wright, G. Chem. Rev. 2005, 105, 391-393. 6. Alder, J. D. Drugs Today 2005, 41, 81-90....
Immunological Effects of Glatiramer Acetate in Multiple Sclerosis Patients
Evaluation of the immunological responses to GA in MS patients revealed that all patients treated with GA developed anti-GA antibodies, whereas placebo-treated patients were negative.74 The antibody level peaked at 3 months after initiation of treatment and reached a level of 8-20-fold above baseline. It decreased at 6 months and remained low. The anti-GA-reactive antibodies were of immunoglobulin G IgG type, with IgG1 levels two- to threefold higher than those of IgG2 at all time points...
Historical Overview
Carvedilol Coreg is commonly referred to as a third-generation beta adrenoceptor blocker beta blocker with vasodilatory and antioxidant properties. These varied activities are attributed to different parts of the carvedilol molecule Figure 1 . Carvedilol was originally discovered in the early 1980s as a novel beta blocker for the primary therapeutic indications of angina and hypertension, which were traditional uses of drugs of this class at the time. However, the true novelty behind carvedilol...
Biographies
Robert R Ruffolo is currently President of Research amp Development for Wyeth Pharmaceuticals, and corporate Senior Vice President of Wyeth. He joined Wyeth in 2000 as Executive Vice President, responsible for Pharmaceutical Research and Development. Prior to joining Wyeth, Dr Ruffolo spent 17 years at SmithKline Beecham Pharmaceuticals where he was Senior Vice President and Director of Biological Sciences, Worldwide. Before joining SmithKline Beecham, Dr Ruffolo spent 6 years at Lilly Research...
Raloxifene Structural Characteristics
Recent progress in our understanding of the molecular biology of estrogen receptor action has provided a great deal of evidence which promises to increase our understanding of the mechanism through which SERMs elicit their tissue-specific effects. This in turn has enhanced interest in raloxifene and increased the interest in developing new tissue-specific SERMs. The identification of numerous coactivators and corepressors150,151 which modulate receptor function and the realization that there...
W w WO O
As noted, eperezolid 2 was the first Upjohn oxazolidinone drug candidate, a piperazinyl monofluorophenyl-5-acetamidomethyl oxazolidinone with a hydroxyacetyl moiety on the piperazine distal nitrogen.45 While this is the identical group that had proved optimal in the 5'-indolinyl series with U-97456 , the sequence of events leading to the identification of eperezolid was somewhat more roundabout than may be obvious. At an early point in the piperazinyl project, the Hutchinson laboratory had...
Conclusion Of Medicinal Chemistry
The past 30 years of drug discovery have seen a procession of breakthrough technologies designed to improve the efficiency and overall success rate of drug discovery programs. Ironically, the fact that drug discovery remains a difficult and risky endeavor despite the use of these technologies has caused some to question the value of these technologies compared to more traditional biologically driven approaches towards drug discovery, with ezetimibe often cited as a case in point. The...
Formation of the Oxazolidinone Working Group
The successful outcomes of the U-82965, U-97456, and U-85910 toxicology studies as well as the poor performance of U-92300 , gave us considerable confidence in our ability to use the 30 day toxicology protocol to identify oxazolidinone series most worthy of continued pursuit - and those unworthy of advancement due to an unacceptably low therapeutic index. The establishment of this knowledge basis contributed directly to the eventual increased support of the oxazolidinone project with the...
Incontinence Severity Index in SAAB
The fact that all efficacy measures showed improvements with duloxetine at all doses but lacked statistical significance for all points suggested that patients were really improving with duloxetine but that the small number of patients coupled with the noise in each of the individual parameters were obscuring the positive signal. Therefore, a factor analysis approach, the incontinence severity index ISI , was developed by Ilker Yalcin.36'37 The underlying supposition in the creation of the ISI...
References Bsz
1. Schwartz, N. B. McCormack, C. E. Annu. Rev. Physiol. 1972, 34, 425-472. 2. Burger, H. G. Int. J. Fertil. 1981, 26, 153-160. 3. Sherman, B. M. Korenman, S. G. J. Clin. Invest. 1975, 55, 699-706. 4. Sherman, B. M. West, J. H. Korenman, S. G. Clin. Endocrinol. Metab. J. Clin. Endocrinol. Metab. 1976, 42, 629-636. 5. Korenman, S. G. Sherman, B. M. Korenman, J. C. Clin. Endocrinol. Metab. 1978, 7, 625-643. 6. Sarto, G. E. Int. J. Gynaecol. Obstet. 1977, 15, 189-192. 7. Nordin, B. E. Horsman, A....
Medicinal Chemistry Summer School
My interest in medicinal chemistry as a scientific discipline also led me to become involved with the Royal Society of Chemistry RSC summer school. My colleague, Dr AM Roe, was Chairman of the RSC Education Committee which advised the RSC on the various courses mounted for postgraduate chemists on specialist topics. These were usually residential and each lasted for approximately 1 week. One such course had started as a week's summer school in medicinal chemistry but it had not attracted enough...
References 1
1. American Heart Association. HeartDisease and Stroke Statistics 2004 Update American Heart Association Dallas, TX, 2003. 2. Davidson, M. H. Toth, P. P Prog. Cardiovasc. Dis. 2004, 47, 73-104. 3. Dunbar, R. L. Rader, D. J. Drug Disc. Today 2004, 1, 169-176. 4. Bruckert, E. Cardiology 2002, 97, 59-66. 5. Shepherd, J. In 73rd European Atherosclerosis Society Congress, Salzburg, Austria, July 7, 2002. 6. Stein, E. Stender, S. Mata, P. Ponsonnet, D. Melani, L. Lipka, L. Suresh, R. Veltri, E. In...
Adrenergic Receptors
SmithKline Beecham originally acquired rights to carvedilol in the US from Boehringer Mannhein now part of Roche with the obligation to develop the drug for angina and hypertension. The original pharmacological profile of carvedilol was that of a vasodilating beta blocker.1'2 A long-standing core team of scientists at SmithKline Beecham, consisting of the authors, as well as Hieble, Nichols and Ohlstein, devoted between one and two decades of their respective lives to understanding every aspect...
Ezetimibe
J W Clader, Schering-Plough Research Institute, Kenilworth, NJ, USA 2007 Elsevier Ltd. All Rights Reserved. 8.07.2 Discovery of the Prototype Azetidinone Cholesterol Absorption 8.07.3 Defining the Nature of the Target 8.07.3.1 Structure-Activity Relationship on the Azetidinone Nucleus 8.07.4 The Discovery of Ezetimibe 8.07.8 Mechanism of Action Studies Atherosclerotic coronary artery disease remains a major cause of death and morbidity worldwide and a significant drain on healthcare resources,...
The Discovery of Posaconazole
Posaconazole15 21 is a novel triazole that has broad-spectrum antifungal activity against Aspergillus spp., Cryptococcus spp., Histoplasma spp., and a variety of other pathogens. In the clinic, posaconazole has been found to be well tolerated, with common side effects being gastrointestinal in origin. Life-threatening opportunistic fungal infections occur in AIDS patients, and also in patients undergoing chemotherapy for cancer, or those who have undergone organ transplants. The older...
The Design of Ezetimibe
Based on the activity of 9, the phenols 10, 11, 12, 13, 14, and 15 were synthesized, and their in vivo activities determined. The results are summarized in Figure 4. Based on the structure-activity relationship as described in Figure 2 and also on the biological activities of the possible metabolites as described in Figure 4, several new analogs were synthesized. Ezetimibe was found to be the most potent among all the analogs synthesized in inhibiting the absorption of cholesterol. The...
o
Figure 1 Structure of tenofovir disoproxil, tenofovir, and the bioconversion pathway. readily undergo passive diffusion across cellular membranes and intestinal mucosa, resulting in low bioavailability after oral administration.6'7 A series of novel prodrugs of tenofovir was designed to overcome the pharmacokinetic limitations of tenofovir.8'9 These prodrugs were engineered to mask the polar phosphonic acid functionality using a novel oxycarbonyloxymethyl linker to allow for passive diffusion...
Reflections on Medicinal Chemistry Since the 1950s
H Timmerman, Vrije Universiteit, Amsterdam, The Netherlands 2007 Elsevier Ltd. All Rights Reserved. 8.02.2 Pharmacochemistry at the Vrije Universiteit Amsterdam 8.02.3 Being a Professor in Amsterdam 8.02.4 The 'New' Histamine Receptors 8.02.5 Histamine, Histamine Receptors, and Ligands as Research Tools When I started to study chemistry at the Vrije Universiteit in Amsterdam in 1956, it was just one hundred years since the history of modern synthetic medicines had started. Perkin had...
G13 Case 2
Figure 1 A HO, R Pr, isoproterenol A MeSO2NH, R iPr soterenol A HOCH2, R tBu, albuterol. reported significant lowering of blood pressure in hypertensives by propranolol, opposite to what was predicted because of its predominant effect on cardiac function rather than peripheral vasculature. By following rather than leading with clinical trials, sotalol was registered first in Europe but its sales were dwarfed by propranolol. In later years, probing clinical research established a significant...